Video

Dr. Wagaskar on the Rationale to Evaluate the Obesity Paradox in Prostate Cancer

Vinayak G. Wagaskar, MBBS, discusses the rationale to evaluate the relationship between obesity paradigm and outcomes in prostate cancer.

Vinayak G. Wagaskar, MBBS, instructor of urology, Mount Sinai, discusses the rationale to evaluate the relationship between obesity and outcomes in prostate cancer.

Several studies have emerged suggesting that morbidly obese individuals with genitourinary malignancies with a high body mass index (BMI) have improved survival compared with patients with a lower BMI, says Wagaskar. This is known as the obesity paradox because the belief is that obese patients would have naturally worse outcomes vs non-obese patients, Wagaskar says.

During the 2021 EAU Congress, findings from a retrospective study demonstrated that BMI is a significant predictor of overall survival in patients with metastatic castration-resistant prostate cancer. Moreover, obese patients had a higher survival probability vs overweight and normal weight patients.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Related Videos
COOMBS
Dr Fakih on the Future of Botensilimab and Balstilimab–Based Therapies in MSS mCRC
Alberto Montero, MD, MBA, CPHQ
Elizabeth Lee, MD, a gynecologic oncologist and the gynecologic oncology program's liaison to the Center for Cancer Therapeutics Innovation at Dana-Farber Cancer Institute
Taliya Lantsman, MD, a hematology/oncology fellow at Beth Israel Deaconess Medical Center
Alvaro Alencar, MD, discusses current unmet needs following the development of covalent BTK inhibitor resistance in CLL.
Melanie A. Sheen, MD
Raajit Rampal, MD, director of the Center for Hematologic Malignancies and director of the Myeloproliferative Neoplasms Program at Memorial Sloan Kettering Cancer Center
Shannon N. Westin, MD, MPH, FACOG, director, Early Drug Development, clinical medical director, professor, Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery, codirector, Ovarian Cancer Moonshot Program, The University of Texas MD Anderson Cancer Center